Tagged with OP

Spain Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is intensifying its commitment to the country with a total investment of EUR 1.3 billion its new global R&D hub in…

Global After seven years at the helm of the pharma industry’s biggest global trade group, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Thomas Cueni is retiring. Having played a key role in coordinating innovative pharma’s successful response to the COVID-19 pandemic among other achievements, Cueni is passing the reins…

USA As healthcare costs are set to be a key issue for voters in the upcoming US presidential election, PhRMA’s Robert Zirkelbach lays out why policymakers must abandon partisan solutions that do not address underlying access and affordability issues. Instead, Zirkelbach urges for greater protection of the USA’s world-leading biopharmaceutical R&D…

China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…

Europe PharmaBoardroom caught up with Niklas Hedberg at DIA Europe 2024 in Brussels to gauge what more needs to be done ahead of the implementation of European HTA regulation in January 2025. Hedberg, who spoke at a host of panels across the event, also gave his take on the EU Pharma…

Europe PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient advocates, industry representatives, and service providers in attendance were treated to a three-day buffet of engaging panels and townhalls with…

Denmark In conversation at DIA Europe 2024 in Brussels, Lars Bo Nielsen lays out the digital transformation that the Danish Medicines Agency has undergone over the past three years and how AI can best be integrated into the work of national regulatory bodies.   What does AI really mean? How can…

India Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse,   Our greatest ability as humans is not to change the world, but to change ourselves Mahatma Gandhi The secret to success in India…

Opinion Writing in the March 2024 edition of the DIA Global Forum magazine, experts from Moderna, Cencora PharmaLex, CureVac, and BioNTech review the scientific potential and regulatory challenges, such as the lack of global harmonization, surrounding gene therapy-based medicinal products. Gene therapy medicinal products (GTMPs), which in the European Union (EU)…

Opinion Writing in the March 2024 edition of the DIA Global Forum magazine, Scott P. Commins of the University of North Carolina School of Medicine, Jasmine Uchi of VeganMed, and Sachin A. Shah of the University of the Pacific address the use of animal-derived ingredients (ADIs) in pharma and outline a…

India Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened up its clinical research regulations and saw a significant drop in trial numbers. However, with a revised regulatory landscape, a…

Global Drawing inspiration from Quentin Tarantino’s directorial breakthrough in the early 1990s, Blue Spoon Consulting’s John Singer explores the pharma sector’s urgent need for a strategic overhaul to ensure success and sustain growth amidst looming patent expirations.   Lex is the flagship investment column of the Financial Times. Its commentaries, currently written…